Pharmaceutical

Home - Products - Pharmaceutical

Antifungal Miconazole Nitrate

  • Product Name: Antifungal Miconazole Nitrate
  • CasNo: 22832-87-7
  • Purity:
  • Appearance: White crystal powder

Mobile/Wechat/WhatsApp: 13666361637

Email:peterkiter@hotmail.com

Inquiry

CasNo: 22832-87-7

Molecular Formula: C18H15Cl4N3O4

Appearance: White crystal powder

China cas 22832-87-7 manufacturer wholesale Antifungal Miconazole Nitrate at affordable price

  • Molecular Formula:C18H15Cl4N3O4
  • Molecular Weight:479.147
  • Appearance/Colour:White crystal powder 
  • Melting Point:170-185 °C 
  • Refractive Index:1.6200 (estimate) 
  • Boiling Point:555.1 °C at 760 mmHg 
  • Flash Point:289.5 °C 
  • PSA:93.10000 
  • Density:1.451g/cm3 
  • LogP:6.63030 

Miconazole nitrate(Cas 22832-87-7) Usage

Pharmacological effects

Miconazole nitrate is a kind of artificially synthetic 1-phenylethyl imidazole derivatives and belongs to imidazole-class broad-spectrum antifungal drug. It is a commonly used drug for treating skin ringworm without containing hormones and without side effects. Its main active ingredient is miconazole. However, miconazole nitrate is now seldom used in China. Its antibacterial spectrum, antibacterial activity and mechanism of action are all similar with clotrimazole. It can be used as a substitute drug when the treatment of amphotericin in deep fungal infection is invalid. It is suitable for treating the systemic, disseminated infection caused by some kinds of fungus such as Cryptococcus neoformans and Candida albicans. The efficacy of absorption via oral administration is poor. After topical administration, the drug is mainly maintained in the lesion place with only a small fraction getting absorbed into the body. In vivo, it is widely distributed in various body tissues and fluids and can penetrate into the inflamed joints, vitreous and the peritoneum, but the concentration in the sputum and saliva is low and it has a poor penetrating capability through the blood-brain barrier and is difficult to penetrate through the blood-brain barrier. It has a plasma protein binding rate of 90%. It is mainly inactive through liver metabolism into inactive metabolites with 14%~22% of the metabolites being excreted through urine, of which less than 1% of drug being in its prototype. 50% of the drug is excreted through the feces via in its prototype form. The half-life of the α-phase is 0.4 hour while the half-life of the β phase is 2.1 hours with the terminal half-life being 20 to 24 hours. [Mechanism of action of the miconazole nitrate] 1. It can interfere with the activity of cytochrome P450, inhibit the ergosterol biosynthesis of the fungal cell membrane, causing damage to the fungal cell membrane and changing its permeability, further resulting in the leakage of the important intracellular material. 2. It can inhibit the biosynthesis of the fungal triglyceride and phospholipid. 3. It can inhibit the activity of the oxidase and peroxidase enzyme, resulting in the excessive accumulation of the hydrogen peroxide inside the cell, further leading to the submicroscopic structural degeneration and necrosis of fungus. 4. To candida albicans, it can suppress the process of the transition from spores into aggressive hyphae. [Antimicrobial spectrum] Miconazole nitrate has an excellent antifungal effect against various kinds of deep fungi (such as Candida albicans, Aspergillus, Cryptococcus neoformans, blastomycosis, coccidioidomycosis and torulopsis), some epidermis fungi and yeasts. It also has antibacterial effect against some kinds of Gram-positive bacteria (such as staphylococcus, streptococcus) and Bacillus (such as Bacillus anthracis). [Clinical application] 1. for serious infections caused by Candida species, including peritonitis, pneumonia and urinary tract infections. Miconazole nitrate can also be used for treating the secondary infection caused by the Gram-positive bacteria. 2. The local administration can be used for treating chronic and extensive mucocutaneous candidiasis, vulvovaginitis candidiasis, tinea, ringworm, jork itch, athlete’s foot, tinea versicoeor and paronychomycosis caused by various kinds of dermatophytes, yeast and other kinds of fungus. 3. Intravenous administration of it can be used for treating serious cryptococcosis, coccidioidomycosis and vice coccidioidomycosis. The above information is edited by the lookchem of Dai Xiongfeng.

Antifungals

Miconazole nitrate is a kind of antifungal agent which is the drug ”Dakelin” which we are familiar with as commonly used drugs for treating skin ringworm. It has various kinds of effects. It inhibit the biosynthesis of ergosterol which is the fungal cell membrane component, causing damage to the cell membrane structure, increasing the membrane permeability, resulting in the leakage of the intracellular components and inhibiting the glucose utilization, preventing the nutrient uptake, and finally leading to fungal cell death. It is therefore suitable for the treatment of tinea, jock itch, ringworm, athlete's foot, tinea versicolor and paronychomycosis as well as the vaginal infection and secondary infection caused by the yeast (such as Candida) and Gram-positive bacteria. It is also effective in treating otitis externa and bacterial skin infections. The common adverse reactions and side effects of miconazole nitrate include: occasional allergy, blisters, burning feeling, redness, itching or other skin irritation. Very rare angioedema, urticaria, eczema, contact dermatitis, erythema, pelvic pain (cramps), vaginal irritation, vaginal secretions and discomfort in the administration site.

Drug Interactions

1. When it is used in combination with anticoagulant drugs such as coumarin or indandione derivative, it can enhance the effects of the later drugs, leading to prolonged prothrombin time. The patient should be subject to close observation and monitoring of prothrombin time as well as adjustment of the dosage of the anti-coagulation drugs. 2. Miconazole nitrate can be used to increase the cyclosporine blood concentration and could increase the risk of renal toxicity. Therefore, when these two drugs are used in combination, we should monitor the blood concentration of cyclosporine. 3. Rifampicin may enhance the metabolism of this product, increase the liver toxicity. When being used in combination with this drug, it can reduce the plasma concentration of this product, leading to the treatment failure. Being used in combination with isoniazid may also reduce the blood concentration of this product. Thus, we should be cautious when use those above drugs in combination with each other. 4. Combination with phenytoin and miconazole nitrate can cause changes in metabolism of these two drugs, and prolong the peak time of this product. When use the two drugs in combination, we should closely monitor their reactions. 5. Combination with hypoglycemic agent can lead to severe hypoglycemia due to inhibit the metabolism of the drug. 6. Combination with cisapride should be tabooed because this can lead to inhibition of the cytochrome P450 metabolic pathways, further causing arrhythmia. There is also risk of arrhythmia when apply miconazole nitrate in combination with astemizole or terfenadin. Therefore, this should also be avoided.

Manufacturing Process

Imidazole is reacted with ω-bromo-2,4-dichloroacetophenone and that product reduced with sodium borohydride.A suspension of 10.3 parts of the α-(2,4-dichlorophenyl)imidazole-1-ethanol thus obtained and 2.1 parts of sodium hydride in 50 parts of dry tetrahydrofuran is stirred and refluxed for 2 hours. After this reaction time, the evolution of hydrogen is ceased. Then there are added successively 60 parts dimethylformamide and 8 parts of 2,4-dichlorobenzyl chloride and stirring and refluxing are continued for another 2 hours. The tetrahydrofuran is removed at atmospheric pressure. The dimethylformamide solution is poured onto water.The product, 1-[2,4-dichloro-β-(2,4 -dichlorobenzyloxy)phenethyl]imidazole, is extracted with benzene. The extract is washed with water, dried, filtered and evaporated in vacuo. From the residual oily free base, the nitrate salt is prepared in the usual manner in 2-propanol by treatment with concentrated nitric acid, yielding, after recrystallization of the crude solid salt from a mixture of 2-propanol, methanol and diisopropyl ether, 1-[2,4-dichloro-β- dichlorobenzyloxy)phenethyl]imidazole nitrate; melting point 170.5°C.

Therapeutic Function

Antifungal

Biological Activity

Antifungal agent. Inhibits lanosterol demethylase and induces formation of reactive oxygen species.

Biochem/physiol Actions

Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary for ergosterol biosynthesis. The inhibition of ergosterol results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with phospholipids in the cell membrane, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and interfere with triglyceride and phospholipid biosynthesis.

Brand name

M-Zole (Actavis); Monistat (Ortho-McNeil); Monistat (Personal Products); Monistat (Johnson & Johnson).

General Description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Miconazole nitrate is an imidazole derivative and a broad spectrum antifungal drug used in the management of fungal outbreak in humans and veterinary animals.

InChI:InChI=1/C18H14Cl4N2O.HNO3/c19-13-2-3-14(16(21)8-13)18(9-24-6-5-23-11-24)25-10-12-1-4-15(20)17(22)7-12;2-1(3)4/h1-8,11,18H,9-10H2;(H,2,3,4)

22832-87-7 Relevant articles

Methods and compositions for intravaginal contraception

-

, (2008/06/13)

A gel formulation, which is inherently s...

22832-87-7 Process route

miconasole nitrate
22832-87-7,27656-15-1,75319-48-1

miconasole nitrate

Conditions
Conditions Yield
miconasole nitrate
22832-87-7,27656-15-1,75319-48-1

miconasole nitrate

2,4 dichlorobenzoic acid
50-84-0

2,4 dichlorobenzoic acid

2,4-dichlorobenzaldeyhde
874-42-0

2,4-dichlorobenzaldeyhde

1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanol; compound with nitric acid
61258-52-4

1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanol; compound with nitric acid

1-[2,4-dichloro-β-(2,4-dichlorophenylcarbonyloxy)phenethyl]-imidazole nitrate
68601-96-7

1-[2,4-dichloro-β-(2,4-dichlorophenylcarbonyloxy)phenethyl]-imidazole nitrate

Conditions
Conditions Yield
With 2,2'-azobis(isobutyronitrile); oxygen; In ethanol; at 77.5 ℃; for 3.4h; under 5171.5 Torr; Further byproducts given;
2.3 % Chromat.
0.7 % Chromat.
1.3 % Chromat.
0.9 % Chromat.

22832-87-7 Downstream products

  • 1777-82-8
    1777-82-8

    (2,4-dichlorophenyl)methanol

  • 50-84-0
    50-84-0

    2,4 dichlorobenzoic acid

  • 874-42-0
    874-42-0

    2,4-dichlorobenzaldeyhde

  • 61258-52-4
    61258-52-4

    1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanol; compound with nitric acid

Leave Your Message

Relevant Products